In a bid to reduce dependents of African countries in the global supply of vaccines and facilitate access in areas where the COVID-19 crisis has highlighted shortages, the Ministry of Health has entered into a partnership with a Belgian Cooperation, Enabel, to contribute to Rwanda’s goal of building a robust ecosystem in the biotech industry and to boost Rwanda’s readiness to manufacture vaccines and other pharmaceutical products.
“We strongly believe in vaccine equity as one of the sustainable ways of dealing with Covid-19, therefore, we are grateful for the partnership with the Belgian Cooperation and look forward to availing vaccines and other pharmaceutical products to a bigger number of beneficiaries by bringing vaccine manufacturing capabilities in the country,” said Dr. Daniel Ngamije, the Minister of Health.
Dirk Deprez, the Resident Representative of Enabel in Rwanda said:
“Enabel is delighted to be contributing to this noble cause of ensuring that the much-needed vaccines and drugs are accessible in Africa thus contributing to the global vision of health equity.”
This partnership aims at supporting ongoing efforts to strengthen the Rwanda Food and Drug Authority (Rwanda FDA) through the provision of key laboratory software (Laboratory Information Management System) and it is subsequent to the agreement signed between the European Union (ELT) and the Rwanda Development Board (RDS) aiming to strengthen the capacity of the Rwanda FDA, which is key to enhancing the attractiveness of Rwanda for future investments in drugs and vaccine manufacturing.
The Ministry of Health and the Government of Rwanda will continue to work closely with the Belgian Cooperation through Enabel to reach the country’s key strategic health and development goals.
No more details were divulged.